|
Rhoads et al. 2011 [4]
|
7
|
3/4
|
Schizophrenia
|
0
|
0.0 %
|
Cell-based assay NR1
|
|
Zandi et al. 2011 [7]
|
46
|
ns
|
Early-stage psychiatric disorder
|
4
|
6.5 %
|
Cell-based assay NR1/NR2B
|
| | |
Schizophrenia 63 %
| | | |
| | |
Atypical psychosis 15 %
| | | |
| | |
Mood disorder 4 %
| | | |
| | |
Bipolar disorder 4 %
| | |
| | |
Major depression 2 %
| | |
| | |
Paranoia 2 %
| | |
|
Haussleiter et al. 2012 [5]
|
50
|
17/33
|
Psychiatric disorder
|
0
|
0.0 %
|
Cell-based assay NR1/NR2B, NR1/NR1
|
|
Masdeu et al. 2012 [6]
|
80
| |
Schizophrenia
|
0
|
0.0 %
|
Cell-based assay NR1
|
|
Tsutsui et al. 2012 [8]
|
51
|
ns
|
Schizophrenia
|
4
|
7.8 %
|
Cell-based assay NR1/NR2B
|
|
5
|
ns
|
Narcolepsy with psychiatric symptom
|
3
|
60.0 %
|
|
Steiner et al. 2013 [9]
|
121
|
77/44
|
Schizophrenia
|
12
|
9.9 %
|
Cell-based assay NR1/NR2B
|
|
70
|
26/44
|
Major depression
|
2
|
2.8 %
| |
|
38
|
14/24
|
Borderline personality disorder
|
0
|
0.0 %
|
|
Hammer et al. 2014 [10]
|
1272
|
780/492
|
Healthy control
|
137
|
10.8 %
|
Cell-based assay NR1/NR2B
|
|
1081
|
723/358
|
Schizophrenia
|
93
|
8.6 %
| |
|
148
|
70/78
|
Affective disorder
|
24
|
16.2 %
|
|
Steiner et al. 2014 [11]
|
357
|
ns
|
Healthy control
|
25
|
7.0 %
|
Indirect immunofluorescence BIOCHIP assay (commercial)
|
|
184
|
ns
|
Schizophrenia
|
18
|
9.8 %
|
|
99
|
ns
|
Major depression
|
5
|
5.1 %
|
|
42
|
ns
|
Borderline personality disorder
|
1
|
2.4 %
|
|
Our report 2015
|
59
|
23/36
|
Total
|
6
|
10.2 %
|
Cell-based assay NR1/NR2B
|
|
44
|
15/29
|
Schizophrenia
|
4
|
9.1 %
| |
|
1
|
1/0
|
Major depression
|
1
|
100.0 %
| |
|
4
|
1/3
|
Undetermined
|
1
|
25.0 %
| |
|
1
|
1/0
|
Nonherpetic limbic encephalitis
|
0
|
0.0 %
| |
|
1
|
0/1
|
Atypical psychosis
|
0
|
0.0 %
|
|
4
|
1/3
|
Acute transient psychosis
|
0
|
0.0 %
|
|
1
|
1/0
|
Bipolar disorder
|
0
|
0.0 %
|
|
2
|
1/1
|
Organic psychosis
|
0
|
0.0 %
|
|
1
|
1/0
|
Mental retardation
|
0
|
0.0 %
|
